The Asthma Research Landscape in Britain
The UK has a strong track record in respiratory research. Centres in Manchester, London, Birmingham, Leicester, Southampton, Belfast, Dundee, and beyond contribute to a national network that feeds into the UK Severe Asthma Registry (UKSAR). This registry collects real-world data from people with severe asthma treated at specialist centres, and it has become a foundation for understanding how treatments work outside the controlled environment of a lab.
One of the most significant developments in recent years has been the arrival of biologic therapies. These are injectable medications that target specific inflammatory pathways rather than simply dampening the whole immune system. The UK approved depemokimab (brand name Exdensur) in late 2025, the first ultra-long-acting biologic dosed just twice a year for asthma with type 2 inflammation. Meanwhile, older biologics like mepolizumab, benralizumab, and dupilumab continue to be studied in real-world settings to see who benefits most and whether some patients can safely reduce their steroid inhaler dose.
The IMP2ART trial, a cluster randomised controlled study across UK primary care sites, is testing whether embedding supported self-management into routine general practice improves asthma outcomes. Other trials are looking at early intervention, including one investigating whether giving house dust mite allergen tablets to infants aged 5 to 12 months can prevent childhood asthma from developing in the first place.
These studies reflect a broader shift in asthma research. Instead of asking "does this drug work?" the question is increasingly "who does this drug work best for, and how little of it can we get away with?"
Types of Asthma Trials Recruiting in the UK
Clinical trials fall into several categories, and knowing which one fits your situation helps narrow the search.
Phase 2 and 3 drug trials test new medications or new uses for existing ones. These are often run through NHS hospitals with dedicated respiratory research teams. The TREAT trial, for instance, is comparing mepolizumab against omalizumab in children with severe asthma to see if one is non-inferior to the other. Such head-to-head comparisons are relatively rare and valuable, as they directly inform prescribing decisions.
Real-world evidence studies draw on registry data rather than assigning treatments. An analysis published in early 2026 looked at biologic effectiveness in patients who would have been excluded from earlier phase 3 trials, confirming that these medications still help people with more complex health profiles.
Dose-reduction studies ask whether patients on biologics can taper their inhaled corticosteroids without losing control. Researchers at the University of Dundee are currently examining this question, measuring airway twitchiness as participants on dupilumab or tezepelumab step down their steroid dose.
Digital health and self-management trials explore whether remote monitoring tools, apps, or structured support programmes reduce exacerbations. The respiratory data hub being established through Health Data Research UK is building the infrastructure to make these kinds of studies faster and more robust.
What Participation Actually Looks Like
Joining a trial is not a passive experience, and it helps to know what to expect. Most asthma trials involve a screening visit where the research team checks your lung function, reviews your medical history, and confirms you meet the eligibility criteria. These criteria can be quite specific. Some trials require a certain eosinophil count, a history of exacerbations despite high-dose inhaled corticosteroids, or a particular age range.
If you qualify, the trial itself might last anywhere from a few months to several years. Visits are typically more frequent than standard clinic appointments, and you may be asked to complete symptom diaries, perform peak flow measurements at home, or wear a monitor. The research team provides all equipment and training.
One participant from the Manchester Severe Asthma Service, who joined a biologic trial after years of oral steroid dependence, described the monitoring as "more thorough than anything I had experienced in routine care, but not intrusive." She noted that the extra attention alone felt reassuring, regardless of whether the study drug worked.
Safety is a reasonable concern. In the UK, all clinical trials of investigational medicinal products must be approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and a research ethics committee. A new clinical trials regulation framework came into effect in April 2026, designed to make the approval process more predictable and efficient, particularly for early-phase studies.
Finding a Trial That Matches Your Situation
There is no single portal for asthma trials in the UK, but several routes lead to the right listing.
The ISRCTN Registry, hosted by BioMed Central, is a primary clinical trial registry recognised by the World Health Organization. Searching for "asthma" and filtering by recruitment status pulls up active UK studies. ClinicalTrials.gov, run by the US National Library of Medicine, also lists trials recruiting in Britain, though the interface can feel less intuitive for UK users.
The NIHR (National Institute for Health and Care Research) Be Part of Research platform allows you to search by condition and location. Many NHS teaching hospitals maintain their own research pages. Imperial College London, the University of Manchester, and the University of Southampton are among the institutions with active respiratory research portfolios.
Your consultant or GP can also be a gateway. People under the care of a severe asthma service are often approached about relevant trials during routine appointments. If you are interested but have not been approached, asking directly is perfectly reasonable.
A practical suggestion: before contacting a research team, make a note of your current medications, your most recent lung function results, and the number of exacerbations you have had in the past year. These details will help the team assess your eligibility quickly.
Comparing Biologic Options Under Study
The table below summarises the biologics most commonly featured in UK asthma trials, based on publicly available information and published registry analyses.
| Biologic | Target | Dosing Frequency | UK Trial Examples | Typical Eligibility |
|---|
| Depemokimab (Exdensur) | IL-5 | Every 6 months | SWIFT, ANCHOR phase III trials | Eosinophilic phenotype, inadequate control on ICS |
| Mepolizumab | IL-5 | Every 4 weeks | TREAT (paediatric non-inferiority) | Severe eosinophilic asthma, age 6+ |
| Benralizumab | IL-5 receptor | Every 4-8 weeks | UKSAR real-world analyses | Eosinophilic, prior exacerbation history |
| Dupilumab | IL-4/IL-13 receptor | Every 2 weeks | Dundee ICS reduction study | Type 2 inflammation, moderate-to-severe |
| Tezepelumab | TSLP | Every 4 weeks | Dundee ICS reduction study | Severe asthma, irrespective of eosinophil level |
| Omalizumab | IgE | Every 2-4 weeks | TREAT paediatric comparison | Allergic asthma, elevated IgE |
Regional Research Hubs Worth Knowing
Asthma trials are not evenly distributed across the UK, and knowing which centres run which studies can save time.
The Scottish Centre of Respiratory Medicine at Ninewells in Dundee has been active in biologic dose-reduction research. Manchester University NHS Foundation Trust hosts one of the country's largest severe asthma services and contributes heavily to UKSAR. Royal Brompton and Harefield Hospitals in London, now part of Guy's and St Thomas', run multiple asthma trials across paediatric and adult populations. Birmingham Women's and Children's Hospital and the University of Birmingham are involved in paediatric asthma research, including the TREAT trial. The Belfast Health and Social Care Trust and Queen's University Belfast have been central to registry-based analyses of biologic outcomes.
The NIHR Clinical Research Network also supports trial delivery across smaller district general hospitals, meaning you do not always need to travel to a major city to participate.
What to Ask Before You Sign Up
Enrolling in a trial is a personal decision, and asking the right questions early prevents disappointment later. Consider asking the research team about the time commitment: how many visits, how long each lasts, and whether travel costs are reimbursed. Clarify what happens if the study drug does not work for you, and whether you can continue it after the trial ends. Some trials have an open-label extension phase that allows this.
Ask about the control arm. In placebo-controlled trials, you may receive a dummy treatment for part or all of the study. Some trials use a crossover design where everyone gets the active drug at some point, but not all do.
Understand the monitoring. Blood tests, questionnaires, and lung function measurements are common. If you dislike needles or find spirometry exhausting, knowing the schedule in advance matters.
Finally, ask how results will be shared. Many research teams now send plain-English summaries to participants once the trial concludes, but this is not universal.
A Few Words of Caution
Not every trial is right for every person. Eligibility criteria exist for safety and scientific reasons, and being turned down for one study does not mean you are unsuitable for all. Some people worry that trial participation means being treated like a guinea pig. In practice, UK research governance is robust, and participants in respiratory trials often report feeling more closely monitored and better supported than in routine care.
The UK Severe Asthma Registry has shown that even patients who would not have met the strict entry criteria for earlier biologic trials can still benefit from these treatments. This finding pushes back against the concern that research is only for the "textbook" patient.
If you are considering a trial, the Health Research Authority website provides plain-English guidance on what to expect, including your rights and the consent process. Asthma + Lung UK, the charity formed by the merger of Asthma UK and the British Lung Foundation, offers a helpline and online resources for people exploring research participation.
The decision to join a clinical trial is rarely straightforward. It means weighing the inconvenience of extra appointments against the possibility of accessing a treatment that might change how you breathe. For some, the motivation is personal. For others, it is the knowledge that their participation shapes the options available to the next person diagnosed. Either way, the UK offers a research environment that is among the most active and carefully regulated in the world.
研究の知恵